Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan.
J Am Coll Cardiol. 2018 Sep 18;72(12):1369-1378. doi: 10.1016/j.jacc.2018.06.067.
Previous studies raised safety concerns on the association between fluoroquinolone treatment and serious collagen disorders, aortic aneurysm and dissection (AA/AD).
This study sought to evaluate this association via a case-crossover analysis in a large national administrative database.
A case-crossover design was used to compare the distributions of fluoroquinolone exposure for the same patient across a 60-day period before the AA/AD event (hazard period) and 1 randomly selected 60-day period (referent period) between 60 to 180 days before the AA/AD events. In the sensitivity analysis, the authors repeated the main analysis using a 1:5 ratio of hazard period to referent period, to adjust for the effect of time-variant confounders. A disease-risk score-matched time control analysis was performed to investigate the potential time-trend bias. The risks were calculated by a conditional logistic regression model.
A total of 1,213 hospitalized AA/AD patients were identified between 2001 and 2011. In the main case-crossover analysis, exposure to fluoroquinolone was more frequent during the hazard periods than during the referent periods (1.6% vs. 0.6%; odds ratio [OR]: 2.71; 95% confidence interval [CI]: 1.14 to 6.46). In the sensitivity analysis, after adjustment for infections and co-medications, the risk remains significant (OR: 2.05; 95% CI: 1.13 to 3.71). An increased risk of AA/AD was observed for prolonged exposure to fluoroquinolones (OR: 2.41 for 3- to 14-day exposure; OR: 2.83 for >14-day exposure). Susceptible period analysis revealed that the use of fluoroquinolone within 60 days was associated with the highest risk of AA/AD. In the case-time-control analysis, there was no evidence that the observed association is due to temporal changes in fluoroquinolone exposure.
Exposure to fluoroquinolone was substantially associated with AA/AD. This risk was modified by the duration of fluoroquinolone use and the length of the hazard period.
先前的研究对氟喹诺酮类药物治疗与严重的胶原疾病、主动脉瘤和夹层(AA/AD)之间的关联提出了安全性担忧。
本研究通过在大型国家行政数据库中进行病例交叉分析来评估这种关联。
采用病例交叉设计,比较 AA/AD 事件发生前 60 天内(危险期)和 60 至 180 天内(参考期)同一患者氟喹诺酮暴露的分布。在敏感性分析中,作者使用危险期与参考期 1:5 的比值重复了主要分析,以调整时变混杂因素的影响。进行疾病风险评分匹配的时间对照分析,以调查潜在的时间趋势偏倚。通过条件逻辑回归模型计算风险。
2001 年至 2011 年间共确定了 1213 例住院 AA/AD 患者。在主要的病例交叉分析中,危险期氟喹诺酮暴露的频率高于参考期(1.6%比 0.6%;比值比[OR]:2.71;95%置信区间[CI]:1.14 至 6.46)。在敏感性分析中,在调整感染和合并用药后,风险仍然显著(OR:2.05;95% CI:1.13 至 3.71)。氟喹诺酮类药物暴露时间延长与 AA/AD 风险增加相关(3 至 14 天暴露的 OR:2.41;>14 天暴露的 OR:2.83)。易感期分析显示,氟喹诺酮类药物在 60 天内使用与 AA/AD 的风险最高相关。在病例时间对照分析中,没有证据表明观察到的关联是由于氟喹诺酮类药物暴露的时间变化所致。
氟喹诺酮类药物暴露与 AA/AD 显著相关。这种风险受氟喹诺酮类药物使用时间和危险期长度的影响。